antiantibody
ozogamicin
ocrelizumab
cergutuzumab
tisotumab
toxin antitoxin
anticorrelate
teplizumab
dorlixizumab
antipolyvalent
autocentromere
talizumab
immunocharacterize
tabalumab
antisynthetase
bispecific
lorvotuzumab
guselkumab
hyperimmunoglobulin
-ab
immunotoxicity
heterophile
caplacizumab
agonistic monoclonal antibody
antiustekinumab
bivatuzumab
sifalimumab
-o-
polytypic
-kin-
presentation
agglutinin
ixekizumab
immunosphere
-ner-
microlymphocytotoxicity
polyantibody
polyvalent
abzyme
elotuzumab
tucotuzumab
immunomolecule
soravtansine
antiimmunoglobulin
heteroclitic
clenoliximab
sonepcizumab
ibritumomab
cytoimmunity